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study question: How well can a single baseline ultrasound assessment of ﬁbroid burden (presence or absence of ﬁbroids and size of
largest, if present) predict future probability of having a major uterine procedure?
summary answer: During an 8-year follow-up period, the risk of having a major uterine procedure was 2% for those without ﬁbroids and
increased with ﬁbroid size for those with ﬁbroids, reaching 47% for those with ﬁbroids ≥4 cm in diameter at baseline.
what is known already: Uterine ﬁbroids are a leading indication for hysterectomy. However, when ﬁbroids are found, there are few
available data to help clinicians advise patients about disease progression.
study design, size, duration: Women who were 35–49 years old were randomly selected from the membership of a large urban
health plan; 80% of those determined to be eligible were enrolled and screened with ultrasound for ﬁbroids ≥0.5 cm in diameter. African-American and white premenopausal participants who responded to at least one follow-up interview (N ¼ 964, 85% of those eligible) constituted the
study cohort. During follow-up (5822 person-years), participants self-reported any major uterine procedure (67% hysterectomies). Life-table
analyses and Cox regression (with censoring for menopause) were used to estimate the risk of having a uterine procedure for women with no
ﬁbroids, small (,2 cm in diameter), medium (2 –3.9 cm), and large ﬁbroids (≥4 cm). Differences between African-American and white
women, importance of a clinical diagnosis of ﬁbroids prior to study enrollment, and the impact of submucosal ﬁbroids on risk were investigated.
participants/materials, setting, methods: There was a greater loss to follow-up for African-Americans than whites (19
versus 11%). For those with follow-up data, 64% had ﬁbroids at baseline, 33% of whom had had a prior diagnosis. Of those with ﬁbroids, 27% had
small ﬁbroids (,2 cm in diameter), 46% had medium (largest ﬁbroid 2 –3.9 cm in diameter), and 27% had large ﬁbroids (largest ≥4 cm in diameter). Twenty-one percent had at least one submucosal ﬁbroid.
main results and the role of chance: Major uterine procedures were reported by 115 women during follow-up. The estimated risk of having a procedure in any given year of follow-up for those with ﬁbroids compared with those without ﬁbroids increased markedly
with ﬁbroid-size category (from 4-fold, conﬁdence interval (CI) (1.4 –11.1) for the small ﬁbroids to 10-fold, CI (4.4 –24.8) for the medium ﬁbroids,
to 27-fold, CI (11.5–65.2) for the large ﬁbroids). This inﬂuence of ﬁbroid size on risk did not differ between African-Americans and whites (P-value
for interaction ¼ 0.88). Once ﬁbroid size at enrollment was accounted for, having a prior diagnosis at the time of ultrasound screening was not
predictive of having a procedure. Exclusion of women with a submucosal ﬁbroid had little inﬂuence on the results. The 8-year risk of a procedure
based on lifetable analyses was 2% for women with no ﬁbroids, 8, 23, and 47%, respectively, for women who had small, medium or large ﬁbroids at
enrollment. Given the strong association of ﬁbroid size with subsequent risk of a procedure, these ﬁndings are unlikely to be due to chance.
Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology 2015. This work is written by (a) US Government employee(s) and is in the public
domain in the US.
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limitations, reasons for caution: Despite a large sample size, the number of women having procedures during follow-up was
relatively small. Thus, covariates such as BMI, which were not important in our analyses, may have associations that were too small to detect with
our sample size. Another limitation is that the medical procedures were self-reported. However, we attempted to retrieve medical records when
participants agreed, and 77% of the total procedures reported were veriﬁed. Our ﬁndings are likely to be generalizable to other African-American
and white premenopausal women in their late 30s and 40s, but other ethnic groups have not been studied.
wider implications of the findings: Though further studies are needed to conﬁrm and extend the results, our ﬁndings provide
an initial estimate of disease progression that will be helpful to clinicians and their patients.
study funding/competing interest(s): Funding came from the Intramural Research Program of the National Institute of Environmental Health Sciences and the Ofﬁce of Research on Minority Health, National Institutes of Health, Health and Human Services (IRB
#OH95-E-N048). The authors have no conﬂicts of interest.

trial registration number: Not applicable.
Key words: uterine leiomyoma / ultrasonography / disease progression / hysterectomy / heath disparity

Uterine leiomyomata (ﬁbroids) are hormonally dependent benign
tumors that develop during reproductive years in the majority of
women (Stewart, 2001; Baird et al., 2003). Many women are asymptomatic, but others experience heavy vaginal bleeding, pelvic pain and/or reproductive problems (Stewart, 2001; Divakar, 2008). There is marked
racial/ethnic disparity in the development of ﬁbroids, with disease
onset estimated to be 10 –15 years earlier for African-Americans than
for whites (Laughlin et al., 2010b). Fibroids are a leading indication for
hysterectomy (Vessey et al., 1992; Farquhar and Steiner, 2002; Marret
et al., 2012). African-Americans have a particularly high rate of hysterectomy for ﬁbroids, 20% by age of menopause compared with 7% in whites
(Myers et al., 2001). The cost of this condition in the USA is estimated at
$6 –34 billion annually (Cardozo et al., 2012).
Clinical diagnosis of ﬁbroids can occur at all stages of disease
development from small, incidentally identiﬁed tumors to large
symptomatic tumors (Divakar, 2008; Laughlin and Stewart, 2011).
Without an approved pharmacologic treatment that limits ﬁbroid
growth and delays symptoms, there has been no impetus for early
diagnosis. Initial treatment is usually focused on watchful waiting or
symptom reduction with analgesics or hormonal contraceptives. In
most cases the ﬁbroids themselves are treated only if symptoms are
severe. The primary options for women with severe symptoms are
major uterine procedures including uterine artery embolization, MRIguided focused ultrasound, and surgery (Segars et al., 2014). Hysterectomy has long been the mainstay treatment in the USA (Laughlin and
Stewart, 2011).
Little is known about disease progression (Jacoby et al., 2014),
though this would be helpful for counseling women. Some women
have a major uterine procedure soon after initial clinical diagnosis
(Hartmann et al., 2006), while others never have such treatment. Of
the ﬁve longitudinal studies of ﬁbroid growth (Ichimura et al., 1998;
Tsuda et al., 1998; DeWaay et al., 2002; Peddada et al., 2008; Mavrelos
et al., 2010), all were short-term and all reported that the individual
tumor growth rates were highly variable. The largest study (n ¼ 262
ﬁbroids followed with MRI for up to a year) found a median growth
of 9% per 6 months, but rates varied from 89% shrinkage to 138%
growth per 6 months (Peddada et al., 2008). Data from the same
sample of tumors showed that rapid growth often came in spurts and
was rarely sustained over time (Baird et al., 2011). Thus, long-term

growth might be quite different from the short-term growth that has
been studied. Almost nothing is known about symptom development
in relation to ﬁbroid growth, though data indicate that women with
large ﬁbroids are more likely to have symptoms than those with small
ﬁbroids (Stewart, 2001; DeWaay et al., 2002; Wegienka et al., 2003;
Dragomir et al., 2010).
The National Institute of Environmental Health Sciences Uterine
Fibroid Study used ultrasound to screen a large, randomly selected
sample of premenopausal African-American and white women for
ﬁbroids. Study participants were then followed for up to 8 years to
assess the occurrence of major uterine procedures. We report the
association between the single baseline ultrasound assessment for
presence of ﬁbroids and tumor size (if present) and the subsequent
occurrence of a major uterine procedure.

Materials and Methods
Study design
The Uterine Fibroid Study (UFS) is a prospective cohort study. Women, age
35 – 49 years, were randomly selected from the membership list of a large
urban health plan and contacted about the study. Approximately 80% of
those found to be eligible were enrolled, and response was similar for
African-Americans and whites (Baird et al., 2003). At enrollment, which occurred in 1996 – 1999, premenopausal participants attended a clinic visit to
give blood, have measurements taken (weight, blood pressure, waist and
hip circumference), and have ultrasound screening for ﬁbroids (unless a
recent sonogram report was available from a recent clinical examination).
Study participants were followed for up to 8 years with interviews to
assess subsequent medical procedures (interview 1 in 2001 – 2002, interview
2 in 2004).

Participants
The initial study population consisted of 1430 women of whom 1323 were
African-American or white women. Fourteen percent of these (n ¼ 182)
were post-menopausal at enrollment (mostly surgically menopausal) and
were not followed prospectively. Eighty-ﬁve percent of the 1141 premenopausal African-American and white women eligible for follow-up completed
either the ﬁrst follow-up, the second follow-up, or both (N ¼ 964, Fig. 1).
Those lost to follow-up were not substantially different from the participants
of the same ethnic group not lost to follow-up based on comparisons of descriptive variables such as age, education, body mass index, smoking habits,
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gravidity or parity. However, a larger percentage of African-Americans were
lost to follow-up than whites (18.6 versus 10.8%). At enrollment, ﬁbroid
status could not be determined for 8% of African-Americans and 6% of
whites (they did not complete the baseline ultrasound and no other data
were available). These women were also excluded from this analysis (ﬁnal
analysis sample ¼ 895).

ﬁbroid. Any questionable sonograms were reviewed by a single radiologist
(M.C.H.). We relied on self-report of ﬁbroid size for a small subset of the
sample who reported a previous ﬁbroid diagnosis, but did not complete
the study ultrasound (n ¼ 28). Exclusion of these women did not change
our ﬁndings. We categorized size of largest ﬁbroid (no ﬁbroids, largest
ﬁbroid ,2 cm, 2 – ,4 cm, ≥4 cm).

Fibroid status assessment

Assessment of major uterine procedures
during follow-up

Pelvic ultrasound examinations were used to assess participant’s ﬁbroid
status regardless of whether or not the participant had had a prior clinical
diagnosis of ﬁbroids. For those who had recently had a pelvic ultrasound
examination (16%), the radiology records from that examination were
used to assess ﬁbroid status. If the prior examination showed no ﬁbroids
and was done within 2 years, it was used; a sonogram showing ﬁbroids was
used if it had been done within 5 years. The study ultrasound for the remainder included both a transabdominal and transvaginal ultrasound examination.
The abdominal portion was used to evaluate any ﬁbroid that arose from the
upper uterus that would not be readily seen with the transvaginal approach
alone. Ultrasound examinations were conducted by experienced sonographers that were certiﬁed by the American Registry of Diagnostic Medical
Sonographers and trained on the study protocol. They were under the
direct supervision of a radiologist with fellowship training in ultrasound
(author M.C.H.). The examinations were performed on ultrasound units
ATL HDI 9, Acuson 128 XP, and Diasonics DRF 400 using transabdominal
(3.5– 5.0 mHz) and transvaginal (5.0– 7.0 mHz) ultrasound probes. The
uterus and ﬁbroids of ≥0.5 cm were identiﬁed. Size of the uterus (volume calculated from three perpendicular diameters using the ellipsoid formula) and
size of the largest ﬁbroid (largest diameter) were measured. Any submucosal
ﬁbroids were noted. Submucosal was deﬁned as adjacent to the endometrium with no visible normal myometrium between endometrium and

Follow-up telephone interviews were conducted ﬁrst in 2001 – 2002 and
again in 2004. We gathered self-reported information on major uterine procedures (excluding pregnancy procedures). Women were asked speciﬁcally
about hysterectomy, myomectomy, hysteroscopic resection, uterine artery
embolization, endometrial ablation and ‘other’. The only ‘other’ procedure
reported was thermal balloon ablation of the endometrium. We were able to
collect medical records and conﬁrm 88 of the 115 procedures identiﬁed. Six
participants refused at the follow-up interview to release their medical
records, 11 agreed but never returned the signed medical release form,
and for 10 the medical provider failed to return the relevant information.

Other enrollment and follow-up data
Baseline interviews asked about demographic information (age, race/ethnicity and education), height, weight history, a full reproductive history, and
lifestyle information including smoking and alcohol drinking. Baseline
weight was measured at the clinic visit. At each follow-up, interviews asked
about information on menstrual characteristics, time of last menstrual
period, menopausal symptoms, weight, any pregnancies since last interview,
and updated lifestyle information. All interviews were conducted by interviewers who were intensively trained on basic interview procedures and
the study interviews in particular. Interviewers completed mock interviews
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Figure 1 Flow chart showing the sample of National Institute of Environmental Health Sciences Uterine Fibroid Study participants available for this
analysis.

4
that were monitored and approved before they collected data from participants, and occasional ongoing interviews were monitored. The staff for each
of the three interviews numbered 10, 15, and 12 interviewers for baseline,
follow-up 1, and follow-up 2, respectively, with several interviewers from
baseline continuing with follow-up interviews.

Statistical analysis

Ethical approval
The research was approved by the NIEHS and George Washington University Human Subjects Review Boards, and participants gave informed consent.

Results
The age distributions of white (N ¼ 380) and African-American
(N ¼ 515) study participants were very similar (Table I). Most had
more than a high school education, but white women tended to have
more education and lower BMI than African-Americans. Only about
40% of whites had given birth, but most African-Americans were
parous. About half of white women had ﬁbroids, and about 20% of
those had large ﬁbroids (≥4 cm diameter). Nearly three-quarters of
African-Americans had ﬁbroids, and nearly a third of those had large
tumors. The majority of whites with ﬁbroids (68%) were new cases

(ﬁbroids were found at the baseline ultrasound, and there had been no
previous diagnosis), while the majority of African-Americans with
ﬁbroids had been previously diagnosed (61%) (Table I).
Women were followed for up to 8 years (5822 person-years of followup, whites ¼ 2502, African-Americans ¼ 3320). Of the 895 women,
800 participated in both follow-ups, while 57 participated in only the
ﬁrst follow-up and 38 participated in only the second follow-up. Twentyfour percent of white women and 20% of African-American women
went through natural menopause during follow-up. Follow-up time
after menopause was not considered in analyses because ﬁbroids
often begin to shrink after menopause. A total of 115 women reported
major uterine procedures during the follow-up (29 white and 86
African-American women). The majority of the procedures were hysterectomies and myomectomies (Table II). The symptoms that led to having
a major uterine procedure were mostly bleeding and pelvic pain
(Table III).
Only 6 of the 323 women without ﬁbroids at enrollment went on
to have a major uterine procedure during their follow-up (2 AfricanAmerican women and 4 white women). All were hysterectomies, ﬁve
for endometriosis or prolapse, and one for both adenomyosis and
ﬁbroids.
The hazard ratios for having a procedure during follow-up increased
dramatically with the ﬁbroid-size category in both African-Americans
and whites. When we combined African-Americans and whites to test
for ethnic differences in the association between ﬁbroid size at enrollment and risk of a uterine procedure during follow-up, we found no
evidence for ethnic differences (P ¼ 0.88). In the combined data the
hazard ratio for a uterine procedure, adjusted for age and ethnicity
(aHR), rose dramatically with size of the largest ﬁbroid (aHR ¼ 4.0,
95% CI ¼ 1.4– 11.1 for ,2 cm, aHR ¼ 10.4, 95% CI ¼ 4.4– 24.8 for
2– ,4 cm, and aHR ¼ 27.4, 95% CI ¼ 11.5–65.2 for ≥4 cm) (Table IV).
In secondary analyses we considered whether women who had a clinical diagnosis of ﬁbroids prior to study enrollment (52% of those with
ﬁbroids), were more likely to have a procedure during follow-up than
those whose ﬁbroids were ﬁrst identiﬁed at the study ultrasound.
When ‘prior diagnosis’ was included in the hazard model along with
the categories for ﬁbroid size, it was not signiﬁcantly related to having a
major uterine procedure during follow-up (aHR ¼ 1.4, 95% CI ¼ 0.9 –
2.2), and the aHRs for each ﬁbroid-size category were not substantially
different from the estimates from the model without adjustment for
prior diagnosis. When we investigated the impact of submucosal ﬁbroids
by excluding the 118 women who had at least one such ﬁbroid, the
ﬁbroid-size-speciﬁc hazard ratios did not change substantially (aHR ¼
2.9 for small, 10.4 for medium, and 31.6 for large ﬁbroids) (Supplementary Table SI). Nor was having a submucosal ﬁbroid a signiﬁcant predictor
of subsequent procedures when it was included as a variable in a hazard
model that included ﬁbroid size (P ¼ 0.59).
Our life-table analysis to calculate the ﬁbroid-size-speciﬁc cumulative
risk of a procedure over the up to 8-year follow-up is shown in Fig. 2. For
those without ﬁbroids at baseline, the cumulative probability of a procedure at 8 years was 2%; it was 8, 23 and 47% for those with small, medium
and large ﬁbroids, respectively. For the latter group, the cumulative risk of
a procedure increased rapidly from the start of follow-up, reaching over
10% during the ﬁrst year, 20% by the end of 2 years, and 30% by the end of
4 years. The cumulative risk for those with medium ﬁbroids exceeded
10% only after 4 years of follow-up. Those with small ﬁbroids still had
only about a 5% cumulative risk after 4 years.
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Analyses were initially conducted for African-Americans and whites separately. We used discrete proportional hazards models to evaluate the association between ﬁbroid size at enrollment and risk of future major uterine
procedures. Time since enrollment was used as the longitudinal variable,
and data were censored at menopause or end of follow-up. The strength
of association was estimated with a hazard ratio, which estimates risk of a subsequent procedure for women in each baseline ﬁbroid-size category relative
to women with no ﬁbroids at baseline. The potential confounders were age at
baseline (enrollment), body mass index (BMI) and recent births, which might
lead to ﬁbroid regression (Laughlin et al., 2010a,b, 2011). BMI and births were
entered as time-dependent variables using both baseline and follow-up data.
BMI was categorized as shown in Table I. For births that occurred during
follow-up, time since birth was coded as continuous in years starting with
‘0’ for the year of the birth. Years prior to any follow-up birth were coded
as ‘9’. Thus, the time-dependent 8-year coding for a participant who had
one birth during the third year of follow-up would be 9,9,0,1,2,3,4,5.
Those not having a birth during follow-up were coded as ‘9’ throughout
their follow-up years. Adjusting for age changed at least one of the hazard
ratios by at least 10% and was the only potential confounder maintained in
the model. We tested for ethnic differences in the association between
ﬁbroid size and the probability of a procedure by combining data for
African-Americans and whites and including interaction terms for ethnicity
by category of ﬁbroid size. Because the associations were similar for
African-Americans and whites (no interaction) we report the hazard ratios
for the combined data set, controlling for ethnicity.
Absolute cumulative risks of a procedure across follow-up time for separate ﬁbroid size categories were calculated using life-table analyses. Women
were followed in the life table until the ﬁrst reported date of either a
uterine procedure, menopause (date of last menstrual period plus 1 year),
or end of follow-up (date of last follow-up interview).
Two secondary analyses were conducted. First we investigated whether
women with a diagnosis of ﬁbroids prior to study enrollment were more
likely to have a procedure even after baseline ﬁbroid size was taken into
account, i.e. the impact of including a variable for prior diagnosis in the
hazard model. Secondly, we investigated the inﬂuence of submucosal ﬁbroids
by re-running the primary hazard model after excluding women with at least
one submucosal ﬁbroid.
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Table I Descriptive characteristics at enrollment, sample from National Institute of Environmental Health Sciences
Uterine Fibroid Study.
Whites
380

........................................
N

(%)

African-Americans
515

.........................................

N

(%)

.............................................................................................................................................................................................
Year of enrollment
1996

72

(19)

96

(19)

1997

160

(42)

224

(44)

1998

148

(39)

193

1999

0

(0)

35–37

77

(20)

109

(21)

38–40

76

(20)

116

(23)

41–43

78

(21)

113

(22)

44–46

82

(21)

109

(21)

47–50

67

(18)

68

(13)

2

(37)
(,1)

Age at baseline (years)

,High school

0

(0)

9

(2)

High school

11

(3)

91

(18)

Some college/no degree

30

(8)

240

(46)

College degree

64

(17)

68

(13)

College plus additional training

62

(16)

45

(9)

212

(56)

60

(12)

Post graduate degree
Missing

1

–

2

–

2

BMI (kg/m )
,25

222

(58)

133

(26)

25–29

91

(24)

154

(30)

30,35

33

(9)

104

(20)

≥35

34

(9)

124

(24)

Smoking
Never

223

(59)

250

(49)

Past

131

(34)

115

(22)
(14)

Current
,10 cigarettes per day
10–20 cigarettes per day
≥20 cigarettes per day

9

(2)

73

10

(3)

37

(7)

7

(2)

40

(8)

Gravidity
0

152

(40)

46

(9)

≥1

228

(60)

469

(91)

0

223

(59)

110

(21)

1

50

(13)

117

(23)

107

(28)

288

(56)

Yes

61

(16)

234

(45)

No

319

(84)

281

(55)

Yes

189

(50)

383

(74)

No

191

(50)

132

(26)

Parity

≥2
Fibroids diagnosed prior to enrollment

Fibroids at baselinea

Continued
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Table I Continued
Whites
380

African-Americans
515

........................................

.........................................

N

N

(%)

(%)

.............................................................................................................................................................................................
Fibroid size (diameter of largest ﬁbroid)
No ﬁbroids
,2 cm

191

(50)

132

(26)

66

(17)

89

(17)

2– 3.99 cm

80

(21)

184

(36)

≥4 cm

43

(11)

110

(21)

191

(51)

132

(27)

37

(10)

81

(17)

144

(39)

274

(56)

Fibroid type
No ﬁbroids
No submucosal
Missing ﬁbroid type

8

–

28

–

a

Includes newly detected and previously diagnosed.

Table II Major uterine procedures during 8 years of
follow-up, National Institute of Environmental Health
Sciences Uterine Fibroid Study.
Whites

African-Americans

..................... ...........................
Total

N 5 29

Table III Reported symptoms that led to having a major
uterine procedure during 8 years of follow-up, National
Institute of Environmental Health Sciences Uterine
Fibroid Study.

(%)

N 5 86

(%)

........................................................................................
Hysterectomy

13

(45)

64

(74)

Myomectomy

9

(31)

4

(5)

Hysteroscopic resection

5

(17)

7

Uterine artery embolization

0

(0)

Endometrial ablation

2

Thermal balloon

0

Symptom

Number of times
reporteda

........................................................................................
Bleeding

72

Pelvic pain

50

(8)

Back Pain

8

9

(11)

Urinary incontinence or urinary frequency

6

(7)

1

(1)

Infertility

4

(0)

1

(1)

Constipation/diarrhea

2

Leg pain

1

Don’t know

1

Other, non-ﬁbroid relatedb

7

Discussion
We followed premenopausal women ages 35– 49 years who had
been randomly selected at baseline from a large health plan. The
8-year probability of having a major uterine procedure was highly
dependent on ultrasound assessed ﬁbroid status at baseline (presence
or absence of ﬁbroids and size of largest, if present). Women with no
evidence of ﬁbroids at baseline had only a 2% cumulative probability of
a uterine procedure, but it rose to 47% for those who had baseline
ﬁbroids ≥ 4 cm in diameter.
Consistent with other studies (Laughlin et al., 2010b), at enrollment
African-American study participants were more likely than whites to
have ﬁbroids, and their ﬁbroids were larger (Baird et al., 2003).
However, when we conducted the follow-up, the probability of a
major uterine procedure during follow-up was similar for AfricanAmericans and whites once baseline ﬁbroid size was taken into
account. A previous study that reported higher rates of hysterectomy
for blacks with ﬁbroids compared with whites with ﬁbroids (Bower
et al., 2009) did not take ﬁbroid size into account.

a
Women can report multiple symptoms. Six women were missing data on symptoms,
and four reported that they did not have symptoms.
b
Includes items such as endometriosis, prolapse and cervical dysplasia.

Our study has several strengths. No previous study has assessed
ﬁbroid status with ultrasound data on ﬁbroid size in a randomly selected
sample of women and then followed them to determine the risk of
a major uterine procedure. Initial response rates were high, thus
limiting selection bias in our ﬁndings. Our sample included both
African-American and white women in sufﬁcient numbers to evaluate
each group separately. The standardized ultrasound examination
reduced misclassiﬁcation of presence and absence of ﬁbroids, and provided a standardized measure of ﬁbroid size. Our detailed questionnaire
data allowed us to evaluate confounding and censor women when they
became naturally menopausal during the follow-up.
Our study also has limitations. We followed women to assess their
major uterine procedures, but we were not able to do periodic systematic
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Table IV Crude and adjusted hazard ratios (HR) for
having a major uterine procedure associated with ﬁbroid
size at enrollment (diameter of largest ﬁbroid), National
Institute of Environmental Health Sciences Uterine
Fibroid Study 8-year follow-up (N 5 895).
Fibroid size

N

HR

95% CIb

aHRa

95% CIb

........................................................................................
No ﬁbroids

323

1.0

–

1.0

–
1.4– 11.1

,2 cm

155

3.9

1.4– 10.6

4.0

2– 3.99 cm

264

10.4

4.4– 24.5

10.4

4.4– 24.8

≥4 cm

153

26.7

11.6–62.4

27.4

11.5–65.2

a

Figure 2 Cumulative probability of having a major uterine procedure
for women with increasing ﬁbroid size (categories based on diameter of
largest ﬁbroid), National Institute of Environmental Health Sciences
Uterine Fibroid Study.

ultrasound examinations during follow-up. Unlike a direct measure of
ﬁbroid growth, our measure of disease progression (time to major
uterine procedure) will vary both with women’s perceptions of symptoms
and with clinical practice. Also, though our baseline sample size was relatively large, the number of women who underwent a procedure was
limited, so small effects would not have been detected. For example,
covariates such as BMI may have effects on the risk of a uterine procedure
that were too small for our study to detect. We had too few Hispanic or
Asian women to evaluate risk of a procedure for these groups.
An aspect of our design that might have led to bias is that our study participants were told their ﬁbroid status after the baseline ultrasound.
Nearly half (48%) had not been previously diagnosed. It seems possible
that this knowledge could have affected their perceptions of symptoms
and future decisions to have major uterine procedures. However, a previous investigation found no evidence that symptom reporting was inﬂuenced by knowledge of ﬁbroids (Wegienka et al., 2004), and treatment is
generally reserved for those with symptoms (Stein and Ascher-Walsh,
2009). Furthermore, when we evaluated the inﬂuence of having had a
clinical diagnosis of ﬁbroids before baseline, it was not important once
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Models adjusted for age and ethnicity.
CI, conﬁdence interval.

b

we accounted for tumor size at baseline. Another limitation is that the
uterine procedures were self-reported, but most were veriﬁed with
medical records.
Perhaps the most important limitation is that we used a single, simple
measure to assess ﬁbroid status at baseline (ﬁbroid presence or absence
and size of largest, if present). Other measures of ﬁbroid burden need to
be investigated such as categories of submucosal, intramural, or subserosal as recommended by the International Federation of Gynecology and
Obstetrics (FIGO) (Munro et al., 2011). We did not have sufﬁciently
detailed ﬁbroid data to use the full FIGO categorization, but we did consider the inﬂuence of submucosal ﬁbroids. First, we excluded women
with any submucosal ﬁbroids. Then we reanalyzed the full data set
with the dichotomous variable ‘any submucosal ﬁbroid’ added to
control for this factor. Neither including the dichotomous variable nor
excluding women with submucosal ﬁbroids changed the results in any
substantial way. However, this sensitivity analysis relies upon our ultrasound measure of ﬁbroid location, which is less accurate than the
more invasive procedures of infusion sonography or hysteroscopy.
To further explore alternative ways of deﬁning baseline ﬁbroid burden,
we have also conducted supplemental analyses using a tumor burden
variable that includes baseline uterine size. This has the advantage of integrating the impact of multiple ﬁbroids (Supplementary Table SII). This
deﬁnition of ﬁbroid burden was again highly predictive. The estimated
risk of a procedure for women with the highest uterine-size category
(≥250 cm3) was 45-fold higher than for the women with no ﬁbroids at
baseline. In addition, the association between this measure of ﬁbroid
burden with risk of a future major uterine procedure was similar for
African-Americans and whites (P-value for interaction ¼ 0.92).
The similar predictive power of simple measures of ﬁbroid burden in
35 –49 year-old African-American and white women may be surprising,
given the higher ﬁbroid prevalence and symptom severity in
African-Americans. However, it is consistent with the idea that the
African-American/white disparity in ﬁbroid-related health issues is primarily attributable to the approximately 10-year earlier onset of this condition in African-American women, not to a difference in how ﬁbroids
impact symptomatology once the tumors are present.
Large ﬁbroids are more likely to cause health problems than small
ﬁbroids (Stewart, 2001; Wegienka et al., 2003; Dragomir et al., 2010),
but information on the natural history of ﬁbroid development is limited
(Ichimura et al., 1998; Tsuda et al., 1998; DeWaay et al., 2002;
Peddada et al., 2008; Mavrelos et al., 2010). The data on short-term
ﬁbroid growth indicate that individual ﬁbroids grow at different rates,
and sporadic growth spurts are common (Peddada et al., 2008; Baird
et al., 2011). Thus, it would not have been surprising to ﬁnd that data
from a single ultrasound would have little predictive beneﬁt. Instead,
the single ultrasound assessment of ﬁbroid size was highly predictive of
future uterine procedures. It is likely that several of the women who
had no ﬁbroids at enrollment developed them during follow-up, but
they remained at low cumulative risk of a procedure. This suggests that
it is rare for ﬁbroids to cause major problems during the ﬁrst few years
of their development. Likewise, women with small ﬁbroids at baseline
were at low cumulative risk. This may indicate that, despite variation in
growth rates, it usually takes many years for small ﬁbroids to grow to a
size that lead to major uterine procedures. A careful, long-term study
of ﬁbroid growth with periodic assessment of ﬁbroid size is needed.
Medical management of ﬁbroids may be at the cusp of transition.
There is a current effort to ﬁnd pharmacological treatments that shrink
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Supplementary data
Supplementary data are available at http://humrep.oxfordjournals.org/.
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